Recently, The Globe and Mail, Canada’s national newspaper, reported on a depressing study about diabetes and it’s costly and horrendous medical complication ...
Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.